Schroder Investment Management Group Sells 62,115 Shares of United Therapeutics Corporation $UTHR

Schroder Investment Management Group lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 67.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,195 shares of the biotechnology company’s stock after selling 62,115 shares during the period. Schroder Investment Management Group’s holdings in United Therapeutics were worth $8,677,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Virtus Investment Advisers LLC raised its stake in shares of United Therapeutics by 56.2% in the 2nd quarter. Virtus Investment Advisers LLC now owns 1,553 shares of the biotechnology company’s stock valued at $446,000 after acquiring an additional 559 shares in the last quarter. F m Investments LLC grew its holdings in United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. Norges Bank bought a new position in shares of United Therapeutics in the second quarter valued at approximately $136,453,000. Hsbc Holdings PLC lifted its stake in shares of United Therapeutics by 2.8% in the second quarter. Hsbc Holdings PLC now owns 184,794 shares of the biotechnology company’s stock worth $53,098,000 after buying an additional 5,088 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $400.56, for a total transaction of $9,012,600.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 593,435 shares of company stock worth $262,583,352. 10.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on UTHR. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. UBS Group boosted their price objective on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. Cantor Fitzgerald lifted their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Trading Up 0.7%

Shares of UTHR stock opened at $484.10 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $492.62. The company has a market capitalization of $20.85 billion, a P/E ratio of 18.34, a P/E/G ratio of 4.78 and a beta of 0.86. The stock has a 50 day moving average of $451.78 and a two-hundred day moving average of $366.63.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the business posted $6.39 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.